Characteristics | CaC group | AR + CaC group | P value |
---|---|---|---|
Number of patients, n | 23 | 85 | - |
Male, n (%) | 14 (61) | 55 (65) | 0.734 |
Age, years | 66 ± 12 | 70 ± 12 | 0.172 |
Total body weight, kg | 56.3 ± 9.3 | 53.8 ± 12.1 | 0.362 |
Dry weight, kg | 54.9 ± 9.1 | 52.3 ± 12.0 | 0.347 |
Dialysis time, min | 199 ± 27 | 212 ± 28 | 0.060 |
Dose of calcium carbonate, g/day | 1.9 ± 1.1 | 2.5 ± 1.3 | 0.062 |
Pre-HD blood urea nitrogen, mg/dL | 53.0 ± 13.2 | 54.2 ± 17.9 [n = 83] | 0.771 |
Pre-HD serum creatinine, mg/dL | 7.53 ± 2.24 | 8.26 ± 2.77 | 0.246 |
Pre-HD estimated GFR, mL/min/1.73 m2 | 6.2 ± 2.0 | 5.9 ± 2.6 | 0.561 |
Serum albumin, g/dL | 3.0 ± 0.6 [n = 20] | 3.3 ± 0.6 [n = 80] | 0.152 |
Alkaline phosphatase, IU/L | 437 ± 336 [n = 10] | 304 ± 188 [n = 20] | 0.266 |
Intact parathyroid hormone, pg/mL | 25 [n = 1] | 93.8 ± 84.7 [n = 14] | - |
Post-HD serum inorganic phosphorus, mg/dL | 2.3 ± 0.7 | 2.1 ± 0.7 | 0.329 |
Post-HD serum calcium, mg/dL | 8.8 ± 0.9 [n = 22] | 9.0 ± 0.6 [n = 84] | 0.238 |
Post-HD corrected serum calcium, mg/dL | 9.6 ± 1.0 [n = 19] | 9.6 ± 0.6 [n = 84] | 0.984 |
Co-morbidities | |||
Hypertension, n (%) | 17 (74) | 62 (73) | 0.926 |
Dyslipidemia, n (%) | 2 (9) | 16 (19) | 0.279 |
Type 2 diabetes, n (%) | 14 (61) | 40 (47) | 0.240 |
Heart disease, n (%) | 8 (35) | 40 (47) | 0.293 |
Peptic ulcer disease, n (%) | 0 (0) | 6 (7) | - |
Mineral and bone disorder, n (%) | 4 (17) | 11 (13) | 0.626 |
Parathyroid disorder, n (%) | 5 (22) | 8 (9) | 0.105 |
Gastric acid reducers | |||
Proton pump inhibitors, n (%) | - | 73 (86) | - |
Histamine H2 receptor antagonists, n (%) | - | 12 (14) | - |
Osteoactive drugs | |||
Vitamin D3 analogues, n (%) | 5 (22) | 24 (28) | 0.533 |
Bisphosphonates, n (%) | 0 (0) | 0 (0) | - |
Calcium sensitizers, n (%) | 0 (0) | 0 (0) | - |